700 Main Street
7 articles with Compass Therapeutics
Julie is co-founder and managing partner of Biomatics Capital Partners.
Compass Therapeutics announced the first patient has been dosed in its multi-center, open-label, first-in-human Phase 1 trial of CTX-471, a fully human monoclonal antibody that binds and activates a unique epitope of the co-stimulatory receptor CD137 expressed on T cells and NK cells.
Compass Therapeutics Announces Issuance of Composition of Matter and Method Patents Covering Its Lead Immuno-oncology Candidate, CTX-471
U.S. Patent and Trademark Office issued three U.S. patents covering certain anti-CD137 antibodies, including its lead therapeutic candidate, CTX-471.
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, will discuss its novel approach to antibody discovery and development and present data on its leading programs in a presentation at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week.
Compass Therapeutics Expands Leadership Team with Appointments of Chief Medical Officer and Chief Financial Officer
Dr. Liu will oversee Compass’ development of a deep pipeline of immuno-oncology and autoimmune disease candidates.
Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a corporate update at the 30th Annual Piper Jaffray Healthcare Conference which takes place November 27-29 in New York, NY.